CureVac

About CureVac

Global biopharmaceutical company specializing in mRNA technology to develop vaccines, cancer therapies, and rare disease treatments by instructing the body to produce proteins

Key facts

Industry

Biotechnology Research

Company size

251–1,000 employees

Headquarters

Tübingen, Baden-Württemberg, Germany

Founded

2000

Revenue

€535MFY2024, publicly reported

Website

curevac.com

LinkedIn

linkedin.com/company/curevac

CureVac in the news

• CureVac stock converts into BioNTech shares after merger

  CureVac shares have converted to BioNTech shares following the acquisition, with BioNTech planning to close former CureVac sites, including the Tübingen headquarters, by the end of 2027.

  ad-hoc-news.de · Oct 4, 2026
• Nach Curevac-Aus in Tübingen: Was macht eigentlich die Curevac-Taskforce der Landesregierung?

  A state task force formed after CureVac's exit from Tübingen is vaguely referencing future spin-off concepts and attempting to attract BioNTech founders.

  tagblatt.de · Oct 3, 2026
• Morning Briefing: Biontech, Curevac – und die Bilanz des Staats als Unternehmer

  The German government experienced a significant loss on its investment in CureVac, while BioNTech is scaling back operations, and the government is trying to block a Chinese acquisition of Zippel.

  handelsblatt.com · Sep 30, 2026
• Biontec schließt Curevac-Werk in Tübingen – Boris Palmer findet das "erschreckend"

  Biontech is closing its former Curevac site in Tübingen and two other locations by early 2028, impacting 1800 employees, despite earlier promises to integrate the Tübingen research and production site.

  badische-zeitung.de · Sep 29, 2026
• Palmer nennt BioNTech-Aus in Tübingen "erschreckend" - und bangt um Arbeitsplätze

  BioNTech is closing three German production sites by 2028, including the former CureVac headquarters in Tübingen, due to decreased COVID-19 vaccine demand, impacting 1,800 jobs.

  swr.de · Sep 28, 2026